Abstract
A series of 2-thiohydantoins were prepared as somatostatin subtype 4 (sst4) ligands. Reaction of a Nsubstituted- L-tryptophan methyl ester with an isothiocyanate in the presence of triethylamine readily afforded the target compounds. The 2-thiohydantoins were evaluated for binding affinities in cell lines expressing somatostatin receptor subtypes 2A (sst2A) and 4 (sst4). Compared to the thiourea NNC-26-9100 (3), all 2-thiohydantoins demonstrated lower binding affinities at sst4. Incorporation of the thiourea moiety into the more rigid 2-thiohydantoin nucleus leads to a loss of conformational freedom and may prevent optimal interaction with sst4.
Keywords: 2-Thiohydantoins, Somatostatin, Isothiocyanates, L-tryptophan methyl ester, Somatostatin receptors, Binding affinity, thiourea, triethylamine, SRIF, gastrointestinal tract, neuromodulator, structurally-related receptors , triethylamine, G-protein-coupled superfamily
Letters in Drug Design & Discovery
Title:Synthesis of 2-Thiohydantoins as Somatostatin Subtype 4 Receptor Ligands
Volume: 9 Issue: 7
Author(s): Xin Wang, David Mealer, Lacey Rodgers, Karin Sandoval, Ken Witt, Carsten Stidsen, Michael Ankersen and A. Michael Crider
Affiliation:
Keywords: 2-Thiohydantoins, Somatostatin, Isothiocyanates, L-tryptophan methyl ester, Somatostatin receptors, Binding affinity, thiourea, triethylamine, SRIF, gastrointestinal tract, neuromodulator, structurally-related receptors , triethylamine, G-protein-coupled superfamily
Abstract: A series of 2-thiohydantoins were prepared as somatostatin subtype 4 (sst4) ligands. Reaction of a Nsubstituted- L-tryptophan methyl ester with an isothiocyanate in the presence of triethylamine readily afforded the target compounds. The 2-thiohydantoins were evaluated for binding affinities in cell lines expressing somatostatin receptor subtypes 2A (sst2A) and 4 (sst4). Compared to the thiourea NNC-26-9100 (3), all 2-thiohydantoins demonstrated lower binding affinities at sst4. Incorporation of the thiourea moiety into the more rigid 2-thiohydantoin nucleus leads to a loss of conformational freedom and may prevent optimal interaction with sst4.
Export Options
About this article
Cite this article as:
Wang Xin, Mealer David, Rodgers Lacey, Sandoval Karin, Witt Ken, Stidsen Carsten, Ankersen Michael and Michael Crider A., Synthesis of 2-Thiohydantoins as Somatostatin Subtype 4 Receptor Ligands, Letters in Drug Design & Discovery 2012; 9 (7) . https://dx.doi.org/10.2174/157018012801319445
DOI https://dx.doi.org/10.2174/157018012801319445 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome
Current Cardiology Reviews Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Current Pharmaceutical Design Research Progress and Future Development Potential of Oridonin in Pharmacological Activities
Current Molecular Pharmacology Molecularly Imprinted Polymers: Artificial Receptors with Wide-Ranging Applications
Micro and Nanosystems Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Association Study of 10 Candidate Genes with Sporadic Alzheimers Disease in a Spanish Population
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Potential Applications of Vasoactive Intestinal Peptide-Based Therapies on Transplantation
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Vascular Disease: A New Progenitor Biology
Current Vascular Pharmacology Antisense Strategies
Current Molecular Medicine Th2 Cytokines in Susceptibility to Tuberculosis
Current Molecular Medicine Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets Meet the Editorial Board
Current Pharmaceutical Design Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design Editorial[Hot Topic:Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Umbilical IgE and Advanced Glycation Products in Association with Allergies in Childhood
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)